292 related articles for article (PubMed ID: 31542384)
1. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
Fleseriu M; Pivonello R; Elenkova A; Salvatori R; Auchus RJ; Feelders RA; Geer EB; Greenman Y; Witek P; Cohen F; Biller BMK
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):855-865. PubMed ID: 31542384
[TBL] [Abstract][Full Text] [Related]
2. Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study.
Pivonello R; Elenkova A; Fleseriu M; Feelders RA; Witek P; Greenman Y; Geer EB; Perotti P; Saiegh L; Cohen F; Arnaldi G
Front Endocrinol (Lausanne); 2021; 12():595894. PubMed ID: 33897615
[TBL] [Abstract][Full Text] [Related]
3. Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS).
Pivonello R; Zacharieva S; Elenkova A; Tóth M; Shimon I; Stigliano A; Badiu C; Brue T; Georgescu CE; Tsagarakis S; Cohen F; Fleseriu M
Pituitary; 2022 Dec; 25(6):911-926. PubMed ID: 36085339
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
5. Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes.
Fleseriu M; Auchus RJ; Greenman Y; Zacharieva S; Geer EB; Salvatori R; Pivonello R; Feldt-Rasmussen U; Kennedy L; Buchfelder M; Biller BM; Cohen F; Heaney AP
Eur J Endocrinol; 2022 Dec; 187(6):859-871. PubMed ID: 36251618
[TBL] [Abstract][Full Text] [Related]
6. Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome.
Geer EB; Salvatori R; Elenkova A; Fleseriu M; Pivonello R; Witek P; Feelders RA; Bex M; Borresen SW; Puglisi S; Biller BMK; Cohen F; Pecori Giraldi F
Pituitary; 2021 Feb; 24(1):104-115. PubMed ID: 33216275
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
Lacroix A; Gu F; Gallardo W; Pivonello R; Yu Y; Witek P; Boscaro M; Salvatori R; Yamada M; Tauchmanova L; Roughton M; Ravichandran S; Petersenn S; Biller BMK; Newell-Price J;
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):17-26. PubMed ID: 29032078
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
[TBL] [Abstract][Full Text] [Related]
9. Levoketoconazole: a novel treatment for endogenous Cushing's syndrome.
Fleseriu M; Auchus RJ; Pivonello R; Salvatori R; Zacharieva S; Biller BMK
Expert Rev Endocrinol Metab; 2021 Jul; 16(4):159-174. PubMed ID: 34380370
[No Abstract] [Full Text] [Related]
10. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients.
Sonino N; Boscaro M; Paoletta A; Mantero F; Ziliotto D
Clin Endocrinol (Oxf); 1991 Oct; 35(4):347-52. PubMed ID: 1752063
[TBL] [Abstract][Full Text] [Related]
11. Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1618-e1630. PubMed ID: 33399817
[TBL] [Abstract][Full Text] [Related]
12. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
[TBL] [Abstract][Full Text] [Related]
13. A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
[TBL] [Abstract][Full Text] [Related]
14. Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.
Lacroix A; Bronstein MD; Schopohl J; Delibasi T; Salvatori R; Li Y; Barkan A; Suzaki N; Tauchmanova L; Ortmann CE; Ravichandran S; Petersenn S; Pivonello R
J Endocrinol Invest; 2020 Nov; 43(11):1613-1622. PubMed ID: 32385851
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study.
Fleseriu M; Iweha C; Salgado L; Mazzuco TL; Campigotto F; Maamari R; Limumpornpetch P
Front Endocrinol (Lausanne); 2019; 10():436. PubMed ID: 31379734
[No Abstract] [Full Text] [Related]
16. Evaluation of ketoconazole as a treatment for Cushing's disease in a retrospective cohort.
Viecceli C; Mattos ACV; Costa MCB; de Melo RB; Rodrigues TDC; Czepielewski MA
Front Endocrinol (Lausanne); 2022; 13():1017331. PubMed ID: 36277689
[TBL] [Abstract][Full Text] [Related]
17. Prolonged treatment of Cushing's disease by ketoconazole.
Sonino N; Boscaro M; Merola G; Mantero F
J Clin Endocrinol Metab; 1985 Oct; 61(4):718-22. PubMed ID: 4031015
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and long-term tolerance of ketoconazole in the treatment of Cushing's disease].
Tabarin A; Navarranne A; Corcuff B; Guerin J; Kern AM; Roger P
Ann Endocrinol (Paris); 1990; 51(1):27-32. PubMed ID: 2171415
[TBL] [Abstract][Full Text] [Related]
19. Hepatic safety of ketoconazole in Cushing's syndrome: results of a Compassionate Use Programme in France.
Young J; Bertherat J; Vantyghem MC; Chabre O; Senoussi S; Chadarevian R; Castinetti F;
Eur J Endocrinol; 2018 May; 178(5):447-458. PubMed ID: 29472378
[TBL] [Abstract][Full Text] [Related]
20. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
